‹ Back
Retatrutide
Why it is for you
Retatrutide fits the deepest metabolic picture: a lot of weight to lose, fatty liver, high triglycerides, a thick waist and rising blood sugar. It suits people who tried GLP-1 or tirzepatide and stalled, because the glucagon arm reaches the liver and energy use in a way they do not. It is best placed on repaired tissue: a gut lining and enteric nerves supported first with BPC-157 and TB-500 tolerate it better. It pairs with high protein, resistance training, and MOTS-c or NAD+ on the cellular energy side. It replaces other GLP-1 products; they are not stacked.
Sources
Read the original sources
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. (Coskun · 2022 · Abstract; full methods not assumed · checked 2026-10-13)
- Retatrutide for metabolic dysfunction-associated steatotic liver disease, Sanyal 2024, Nature Medicine (Abstract · checked 2026-10-13)
- Type 2 diabetes and obesity: the present and future of incretin therapy, Shestakova and Bashlykova 2025, Therapeutic Archive (Russia) (Summary · checked 2026-10-13)